An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression

Cancer Gene Therapy

Volumn 10, Issue 7, 2003, Pages 559-570

  Campbell, Mel ^a,b   Qu, Shimian ^a   Wells, Sam ^a   Sugandha, Herlina ^a   Jensen, Roy A ^a  

^a Vanderbilt Ingram Compreh Cancer C ^*  (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Adenovirus; Imaging; Integrin; Tumor suppressor

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BRCA1 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN MOTIF; REPORTER GENE; SPECIES COMPARISON; TRANSGENE; TUMOR CELL CULTURE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, BRCA1; GENES, REPORTER; GENETIC VECTORS; HUMANS; INTEGRINS; MICE; OLIGOPEPTIDES; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MURINAE; MUS MUSCULUS;

EID: 0037818311     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700599     Document Type: Article

References (76)

1. Bergelson J, Cunningham J, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320-1323.
2. Tomko R, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA. 1997;94:3352-3356.
3. Bergelson J, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virology. 1998;72:415-419.
4. Wickham T, Mathias P, Cheresh D, et al. Integrins alpha V Beta3 and alpha V Beta5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309-319.
5. Nemerow G. Cell receptors involved in adenovirus entry. Virology. 2000;274:1-4.
6. Fechner H, Haack A, Wang H, et al. Expression of coxsackie adenovirus receptor and alpha v-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy. 1999;6:1520-1535.
7. Krasnykh V, Dmitriev I, Navarro J, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 2000;60:6784-6787.
8. Curiel D. Rational design of viral vectors based on rigorous analysis of capsid structures. Mol Ther. 2000;1:3-4.
9. Dmitriev I, Krasnykh V, Miller C, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706-9713.
10. Miller C, Buchsbaum DJ, Reynolds P, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 1998;58:5738-5748.
11. Krasnykh V, Dmitriev I, Mikheeva G, et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998;72:1844-1852.
12. Li Y, Pong R, Bergelson J, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res. 1999;59:325-330.
13. Cripe T, Dunphy E, Holub A, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001;61:2953-2960.
14. Zeimet A, Muller-Holzner E, Schuler A, et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Therapy. 2002;9:1093-1100.
15. Wickham T, Roelvink P, Brough DE. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 1996;14:1570-1573.
16. Wickham T, Tzeng E, Shears II LL, et al. Increased in vitro gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997;71:8221-8229.
17. Krasnykh V, Belousova N, Korokhov N, et al. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol. 2001;75:4176-4183.
18. Seki T, Dmitriev I, Kashentseva E, et al. Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines. J Virol. 2002;76:1100-1108.
19. Staba M, Wickham T, Kovesdi I, et al. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 2000;7:13-19.
20. Vigne E, Mahfouz I, Dedieu J, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol. 1999;73:5156-5161.
21. Wickham T, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Therapy. 1995;2:750-756.
22. Dmitriev I, Kashentseva E, Curiel D. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol. 2002;76:6893-6899.
23. Einfeld D, Schroeder R, Roelvink P, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol. 2001;75:11284-11291.
24. Seki T, Dmitriev I, Suzuki K, et al. Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Therapy. 2002;9:1101-1108.
25. Hemminki A, Zinn K, Liu B, et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst. 2002;94:741-749.
26. Casado E, Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res. 2001;7:2496-2504.
27. Nakamura T, Sato K, and Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther. 2002;13:613-626.
28. Okada Y, Okada N, Nakagawa S, et al. Fiber-mutant technique can augment gene transduction efficacy and antitumor effects against established murine melanoma by cytokine-gene therapy using adenoviral vectors. Cancer Lett. 2002;177:57-63.
29. Venkitaraman A. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182.
30. Welcsh P, Lee M, Gonzalez-Hernandez R, et al. BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA. 2002;99:7560-7565.
31. Harkin D, Bean J, Miklos D, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999;97:575-586.
32. Scully R, Ganesan S, Brown M, et al. Location of BRCA1 in human breast and ovarian cancer cells. Science. 1996;272:123-125.
33. Wilson C, Payton M, Pekar S, et al. BRCA1 protein products: Antibody specificity. Nat Genet. 1996;13:264-265.
34. Chen Y, Farmer A, Chen C, et al. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 1996;56:3168-3172.
35. Holt J, Thompson M, Szabo C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet. 1996;12:298-302.
36. Wilson C, Payton M, Elliott G, et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta 11b. Oncogene. 1997;14:1-16.
37. Aprelikova O, Fang B, Meissner E, et al. BRCA1-associated growth arresggt is RB-dependent. Proc Natl Acad Sci USA. 1999;96:11866-11871.
38. Campbell M, Apreikova O, Van der Meer R, et al. Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brcal genes. Cancer Gene Ther. 2001;8:231-239.
39. Shao N, Chai Y, Shyam E, et al. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene. 1996;13:1-7.
40. Thangaraju M, Kaufmann S, Couch F. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem. 2000;275:33487-33496.
41. Sobczak K, Krzyzosiak W. Structural determinants of BRCA1 translational regulation. J Biol Chem. 2002;277:17349-17358.
42. Xu C, Brown M, Chambers J, et al. Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet. 1995;4:2259-2264.
43. Arizti P, Fang L, Park I, et al. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol Cell Biol. 2000;20:7450-7459.
44. Blagosklonny M, An W, Melilo G, et al. Regulation of BRCA1 by protein degradation. Oncogene. 1999;18:6460-6468.
45. Chen A, Kleiman F, Manley J, et al. Autoubiquitination of the BRCA1-BARD1 RING ubiquitin ligase. J Biol Chem. 2002;277:22085-22092.
46. Aprelikova O, Pace A, Fang B, et al. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem. 2001;276:25647-25650.
47. Tait D, Obermiller P, Redlin-Frazier S, et al. A phase I trial of retroviral BRCA1 sv gene therapy in ovarian cancer. Clin Cancer Res. 1997;3:1959-1968.
48. Tait D, Obermiller P, Hatmaker A, et al. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin Cancer Res. 1999;5:1708-1714.
49. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380.
50. He T-C, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509-2514.
51. Tomlinson G, Chen T, Stastny V, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res. 1998;58:3237-3242.
52. Yuan Y, Kim W, Han H, et al. Establishment and characterization of human ovarian carcinoma cell lines. Gynecol Oncol. 1997;66:378-387.
53. Hsu K, Lonberg-Holm K, Alstein B, et al. A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol. 1988;62:1647-1652.
54. Sweeney T, Mailander V, Tucker A, et al. Visualizing the kinetics of tumor cell clearance in living animals. Proe Natl Acad Sci USA. 1999;96:12044-12049.
55. Welcsh P, King M-C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705-713.
56. Wu L, Wang Z, Tsan J, et al. Indentification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet. 1996;14:430-440.
57. Brzovic P, Rajagopal P, Hoyt D, et al. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol. 2001;8:833-837.
58. Hashizume R, Fukuda M, Maeda I, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem. 2001;276, 14537-14540.
59. Fabbro M, Rodriguez J, Baer R, et al. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem. 2002;277:21315-21324.
60. Lorick K, Jensen J, Fang S, et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA. 1999;96, 11364-11369.
61. Ruffner H, Joazeiro C, Hemmati D, et al. Cancerpredisposing mutations within the RING domain of BRCAI: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA. 2001;98:5134-5139.
62. Contag P, Olomu I, Stevenson D, et al. Bioluminescent indicators in living mammals. Nat Med. 1998;4:245-247.
63. Kasono K, Blackwell J, Douglas J, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res. 1999;5:2571-2579.
64. Blackwell J, Li H, Navarro J, et al. Using a tropis-mmodified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther. 2000;11:1657-1669.
65. Kanerva A, Wang M, Bauerschmitz G, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther. 2002;5:695-704.
66. Hemminki A, Belousova N, Zinn K, et al. An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther. 2001;4:223-231.
67. Koizumi N, Mizuguchi H, Hosono T, et al. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochem Biophys Acta. 2001;1569:13-20.
68. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Therapy. 1999;6:1336-1339.
69. Omori N, Mizuguchi H, Ohsawa K, et al. Modification of a fiber protein in an adenovirus vector improves in vitro gene transfer efficiency to the mouse microglial cell line. Neurosci Lett. 2002;324:145-148.
70. Bauerschmitz G, Lam J, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 2002;62:1266-1270.
71. Bilbao G, Contreras J, Dmitriev I, et al. Genetically modified adenovirus vector containing an RGD peptide in the HI loop of the fiber knob improves gene transfer to nonhuman primate isolated pancreatic islets. Am J Transplant. 2002;2:237-243.
72. VanderWaak T, Wang M, Gomez-Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol. 1999;74:227-234.
73. Okegawa T, Pong R, Li Y, et al. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of CAR protein structure. Cancer Res. 2001;61:6592-6600.
74. Reynolds P, Nicklin S, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol. 2001;19:838-842.
75. Selvakumaran M, Bao R, Crijns A, et al. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res. 2001;61:1291-1295.
76. Casado E, Nettelbeck D, Navarro J, et al. Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol. 2001;82:229-237.